Page 51 - 南京医科大学学报自然科学版

第43卷第9期 甘晓霞，叶黄戍，王 嫱，等. 基于简易危险分层探索血清sST2评估结缔组织病相关肺动脉高压
2023年9月 病情严重程度的研究［J］. 南京医科大学学报（自然科学版），2023，43（9）：1223-1229 ·1229 ·

in acute heart failure［J］. JACC Heart Fail，2017，5（4）： ［20］ LI X，SUN X，HUANG Y，et al. Simplified risk stratifica⁃
287-296 tion for pulmonary arterial hypertension associated with
［10］ ARINGER M，COSTENBADER K，DAIKH D，et al. 2019 connective tissue disease［J］. Clin Rheumatol，2019，38
European League Against Rheumatism/American College （12）：3619-3626
of Rheumatology classification criteria for systemic lupus ［21］ WANG J，WANG Y，LI X，et al. Serum uric acid is associ⁃
erythematosus［J］. Ann Rheum Dis，2019，78（9）：1151- ated with disease severity and may predict clinical outcome
1159 in patients of pulmonary arterial hypertension secondary to
［11］ SHIBOSKI C H，SHIBOSKI S C，SEROR R，et al. 2016 connective tissue disease in Chinese：a single⁃center retro⁃
American College of Rheumatology/European League spective study［J］. BMC Pulm Med，2020，20（1）：272
Against Rheumatism classification criteria for primary ［22］ SUN Y，WANG L，MENG X，et al. Soluble ST2 and mixed
Sjögren’s syndrome：a consensus and data⁃driven metho⁃ venous oxygen saturation for prediction of mortality in pa⁃
dology involving three international patient cohorts［J］. tients with pulmonary hypertension［J］. J Thorac Dis，
Ann Rheum Dis，2017，76（1）：9-16 2021，13（6）：3478-3488
［12］ DEN H F V，DINESH K，JAAP F，et al. 2013 classifica⁃ ［23］CARLOMAGNO G，MESSALLI G，MELILLO R M，et al.
tion criteria for systemic sclerosis：an American college of Serum soluble ST2 and interleukin⁃33 levels in patients
rheumatology/European league against rheumatism collabo⁃ with pulmonary arterial hypertension［J］. Int J Cardiol，
rative initiative［J］. Ann Rheum Dis，2013，72（11）：1747- 2013，168（2）：1545-1547
1755 ［24］ ZHENG Y G，YANG T，HE J G，et al. Plasma soluble ST2
［13］ SHARP G C，IRVIN W S，TAN E M，et al. Mixed connec⁃ levels correlate with disease severity and predict clinical
tive tissue disease⁃an apparently distinct rheumatic dis⁃ worsening in patients with pulmonary arterial hypertension
ease syndrome associated with a specific antibody to an ［J］. Clin Cardiol，2014，37（6）：365-370
extractable nuclear antigen（ENA）［J］. Am J Med，1972， ［25］ LUCIA A C，SILVIA L，SERGIU H，et al. Serum levels of
52（2）：148-159 the soluble IL ⁃ 1 receptor family member ST2 and right
［14］ 杨媛华.《中国肺动脉高压诊断与治疗指南（2021版）》 ventricular dysfunction［J］. Biomark Med，2014，8（1）：95⁃
解读——肺动脉高压的诊断［J］. 中国实用内科杂志， 106
2021，41（8）：696-699 ［26］ MARON B A，BRITTAIN E L，HESS E，et al. Pulmonary
［15］ PULIDO T，CHANNICK R N，DELCROIX M，et al. Long⁃ vascular resistance and clinical outcomes in patients with
term survival and safety with macitentan in patients with pulmonary hypertension：a retrospective cohort study［J］.
pulmonary arterial hypertension： results from the Lancet Respir Med，2020，8（9）：873-884
SERAPHIN study and its open⁃label extension［J］. Am J ［27］ SAVALE L，AKAGI S，TU L，et al. Serum and pulmonary
Respir Crit Care Med，2017，195：A2294 uric acid in pulmonary arterial hypertension［J］. Eur
［16］ GALIE N，GAINE S，CHANNICK R，et al. 3016 long ⁃ Respir J，2021，58（2）：2000332
term survival and safety with selexipag in patients with ［28］PLÁCIDO R，CORTEZ ⁃ DIAS N，ROBALO M S，et al.
pulmonary arterial hypertension：results from the GRIPH⁃ Prognostic stratification in pulmonary hypertension：a
ON study and its open⁃label extension［J］. Eur Heart J， multi⁃biomarker approach［J］. Rev Port Cardiol，2017，36
2018，39（suppl1）：631 （2）：111-125
［17］ GALIE N，MCLAUGHLIN V V，RUBIN L J，et al. An ［29］ CHIDA A，SATO H，SHINTANI M，et al. Soluble ST2 and
overview of the 6th world symposium on pulmonary hyper⁃ N ⁃ terminal pro ⁃ brain natriuretic peptide combination.
tension［J］. Eur Respir J，2019，53（1）：1802148 Useful biomarker for predicting outcome of childhoodpul⁃
［18］ BOUCLY A，WEATHERALD J，SAVALE L，et al. Risk monary arterial hypertension［J］. Circ J，2014，78（2）：
assessment，prognosis and guideline implementation in 436-442
pulmonary arterial hypertension［J］. Eur Respir J，2017， ［30］ LUK K S，IP C，GONG M Q，et al. A meta⁃analysis of solu⁃
50（2）：1700889 ble suppression of tumorigenicity 2（sST2）and clinical
［19］DAVID K，BARBRO K，CLARA H，et al. A comprehen⁃ outcomes in pulmonary hypertension［J］. J Geriatr Cardiol，
sive risk stratification at early follow⁃up determines prog⁃ 2017，14（12）：766-771
nosis in pulmonary arterial hypertension［J］.Eur Heart J， ［收稿日期］ 2022-11-24
2018，39（47）：4175-4181 （本文编辑：陈汐敏）